There are currently 10 active clinical trials seeking participants for NASH - Nonalcoholic Steatohepatitis research studies. The states with the highest number of trials for NASH - Nonalcoholic Steatohepatitis participants are Texas, Florida, California and Arizona.
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
NCT06528314
Recruiting
This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in subjects with compensated cirrhosis due to NASH/MASH.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
05/01/2025
Locations: Akero Clinical Study Site, Birmingham, Alabama +208 locations
Conditions: NASH - Nonalcoholic Steatohepatitis, MASH - Metabolic Dysfunction-Associated Steatohepatitis
Register for Updates
Study to Evaluate Efficacy, Safety and Tolerability of HM15211(efocipegtrutide) in Subjects
NCT04505436
Recruiting
This study is a phase 2 study to Evaluate Efficacy, Safety and Tolerability of HM15211 Treatment for 12 Months in Subjects with Biopsy Confirmed NASH
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
03/20/2025
Locations: North Alabama GI Research Center, Huntsville, Alabama +59 locations
Conditions: NASH - Nonalcoholic Steatohepatitis
Register for Updates
Feasibility, Safety and Acceptability of a Mobile Health Delivered Exercise Training Program in Patients with Nonalcoholic Steatohepatitis
NCT06195943
Recruiting
This study will be a pilot study to evaluate the feasibility, safety and acceptability of Exercise and Liver FITness (EL-FIT), a mHealth exercise training program previously validated in patients with cirrhosis in patients with nonalcoholic steatohepatitis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/11/2025
Locations: Penn State Hershey Medical Center, Hershey, Pennsylvania
Conditions: NASH - Nonalcoholic Steatohepatitis, NASH, Exercise, Liver
Register for Updates
Statins for the Treatment of NASH
NCT04679376
Recruiting
The purpose of this research study is to determine whether the study drug, atorvastatin (Lipitor®), is safe and effective in improving the features of NASH.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
02/03/2025
Locations: Mayo Clinic Minnesota, Rochester, Minnesota +1 locations
Conditions: NASH - Nonalcoholic Steatohepatitis
Register for Updates
Nonalcoholic Fatty Liver Disease in HIV Database
NCT05023044
Recruiting
Nonalcoholic fatty liver disease (NAFLD) is a spectrum of liver conditions associated with fat accumulation that ranges from benign, non-progressive liver fat accumulation to severe liver injury, cirrhosis, and liver failure. The spectrum of NAFLD encompasses simple nonalcoholic steatosis (nonalcoholic fatty liver \[NAFL\]) and nonalcoholic steatohepatitis (NASH) in which there is evidence of hepatocellular injury and/or fibrosis. NAFLD is the most common liver disease in adults and the second l... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/14/2025
Locations: University of Alabama, Birmingham, Alabama +7 locations
Conditions: NAFLD, NASH - Nonalcoholic Steatohepatitis, Hiv
Register for Updates
Investigating the Link Between Type 2 Immunity and NAFLD in Human Obesity
NCT04232566
Recruiting
This study is being done to better understand the relationship between inflammation in adipose tissue (AT), abnormal deposition of fat around the liver and how this affects its appearance and function and ultimately insulin resistance.
Gender:
ALL
Ages:
Between 30 years and 70 years
Trial Updated:
09/10/2024
Locations: Mayo Clinic in Arizona, Scottsdale, Arizona
Conditions: Obesity, Morbid, NASH - Nonalcoholic Steatohepatitis, Chronic Inflammation
Register for Updates
Vertical Sleeve Gastrectomy and Lifestyle Modification for the Treatment of Non-Alcoholic Steatohepatitis
NCT03587831
Recruiting
Participants meeting study entry criteria are randomized with equal probability to one of two study groups: (1) Lifestyle modification or (2) Vertical Sleeve Gastrectomy (VSG) with Iifestyle modification, followed for 12 months. The primary goal for the trial is to determine if the investigators can recruit, randomize, and retain participants to perform invasive and non-invasive measurements of NASH and fibrosis, deliver lifestyle modification and demonstrate the safety of VSG. The investigators... Read More
Gender:
ALL
Ages:
Between 30 years and 70 years
Trial Updated:
09/09/2024
Locations: University of San Fransisco, San Francisco, California +1 locations
Conditions: NASH - Nonalcoholic Steatohepatitis
Register for Updates
Estrogen Administration for the Treatment of NASH in Postmenopausal Women
NCT04833140
Recruiting
Non-alcoholic fatty liver disease (NAFLD) is a growing epidemic in the United States. Despite this, the treatment options remain limited. Preclinical and preliminary clinical data suggest that estrogen deficiency plays an important role in the pathology of steatosis, inflammation and fibrosis in non-alcoholic steatohepatitis (NASH), the progressive form of NAFLD. Post-menopausal women are a growing population with particularly high risk of NASH due to their lack of estrogen. This study will exam... Read More
Gender:
FEMALE
Ages:
Between 45 years and 70 years
Trial Updated:
07/30/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: NASH - Nonalcoholic Steatohepatitis
Register for Updates
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )
NCT04849728
Recruiting
This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis histological stage F2 or F3
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/24/2024
Locations: Pinnacle Research Group, Anniston, Alabama +493 locations
Conditions: NASH - Nonalcoholic Steatohepatitis
Register for Updates
Non-Invasive Quantification of Liver Health in NASH (N-QUAN)
NCT04054310
Recruiting
To evaluate, in patients with suspected NASH referred for liver biopsy, the diagnostic performance of CT1 at discriminating those with NAS≥4 \& F≥2 from those without.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
09/07/2023
Locations: Arizona Liver Health, Chandler, Arizona +6 locations
Conditions: NASH - Nonalcoholic Steatohepatitis
Register for Updates